Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Chemomab Therapeutics ( (CMMB) ) has shared an update.
On May 5, 2026, Chemomab Therapeutics held its adjourned annual general shareholders meeting in Ramat Gan, Israel, where investors approved key corporate governance items under Israeli law. Shareholders re-elected Class II directors Neil Cohen and Claude Nicaise and endorsed an updated compensation policy for the company’s office holders and directors.
Investors also authorized an increase in Chemomab’s authorized share capital and a corresponding amendment to its articles of association, a move that could provide additional flexibility for future financings or strategic transactions. In addition, Somekh Chaikin, a member firm of KPMG International, was re-appointed as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2026, supporting continuity in Chemomab’s financial oversight and reporting.
The most recent analyst rating on (CMMB) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on Chemomab Therapeutics stock, see the CMMB Stock Forecast page.
Spark’s Take on CMMB Stock
According to Spark, TipRanks’ AI Analyst, CMMB is a Neutral.
The score is primarily constrained by weak financial fundamentals (pre-revenue, ongoing losses, and negative free cash flow) and a technically weak price trend below major moving averages. Valuation contributes limited support due to the negative P/E and lack of dividend yield data.
To see Spark’s full report on CMMB stock, click here.
More about Chemomab Therapeutics
Chemomab Therapeutics Ltd. is an Israel-based biopharmaceutical company listed in the United States as a foreign private issuer. The company operates under Israeli corporate law and maintains listings and registration statements with the U.S. Securities and Exchange Commission, reflecting its focus on accessing global capital markets for its drug development activities.
Average Trading Volume: 66,606
Technical Sentiment Signal: Sell
Current Market Cap: $11.65M
See more data about CMMB stock on TipRanks’ Stock Analysis page.